The goal of the proposed research is to develop a potent, pharmacologically useful inhibitor of the CD45 protein tyrosine phosphatase. CD45 is a transmembrane protein having a highly glycosylated extracellular region and a cytosolic domain which possesses tyrosine phosphatase activity. CD45 plays a critical role in the activation of both T- and B-lymphocytes, thus inhibitors of CD45 may represent new immunomodulators or anti-inflammatory drugs. In this proposal we will: l) Design and synthesize novel inhibitors of the CD45 protein tyrosine phosphatase based on a nonhydrolyzable pseudosubstrate approach: 2) Evaluate the new compounds as inhibitors in an in vitro assay. The compounds developed in these studies will greatly increase our knowledge of the structure-activity relationships for protein tyrosine phosphatase inhibitors and may lead to the development of new research tools and therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI034653-01
Application #
2069802
Study Section
Special Emphasis Panel (ZRG7-SSS-Z (05))
Project Start
1993-09-01
Project End
1994-02-28
Budget Start
1993-09-01
Budget End
1994-02-28
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Biomol Research Laboratories, Inc.
Department
Type
DUNS #
City
Plymouth Meeting
State
PA
Country
United States
Zip Code
19462